Kura Oncology (KURA) Revenue (2025 - 2026)
Kura Oncology (KURA) posted quarterly Revenue of $18.3 million for Q1 2026, up 29.47% year-over-year from $14.1 million in Q1 2025, and up 5.36% quarter-over-quarter from $17.3 million in Q4 2025.
Powered by 
Analysis
Kura Oncology (KURA) Revenue (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Revenue for 2 consecutive years, with $18.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 29.47% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $71.6 million (changed N/A YoY), while the FY2025 annual figure was $67.5 million, up 25.24% from the prior year.
- Revenue rose to $18.3 million in Q1 2026 per KURA's latest filing, from $17.3 million in the prior quarter.
- Across five years, Revenue topped out at $20.8 million in Q3 2025 and bottomed at $14.1 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Kura Oncology | 1.17 Bn | 1.17 Bn | 20.63 Mn | 20.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.87 Mn |
| Mar 31, 2026 | 18.27 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 20.75 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.11 Mn |